[144] Akero Therapeutics, Inc. SEC Filing
Akero Therapeutics (AKRO) submitted a Form 144 reporting the proposed sale of 50,000 shares of common stock via J.P. Morgan Securities LLC on NASDAQ, with an aggregate market value reported as $2,414,000 and approximately 79,988,975 shares outstanding. The filing shows the shares were acquired by a stock option exercise and the acquisition date, payment date and approximate sale date are all listed as 08/12/2025, with payment in cash.
The form discloses no securities sold in the past three months and includes the seller鈥檚 representation about not possessing undisclosed material adverse information. Several issuer/filer identification fields in the provided content are blank, so the filing text here omits the named filer and named person for whose account the securities are to be sold.
Akero Therapeutics (AKRO) ha presentato un Modulo 144 che segnala la vendita proposta di 50.000 azioni ordinarie tramite J.P. Morgan Securities LLC sul NASDAQ, con un valore di mercato complessivo riportato pari a $2,414,000 e circa 79,988,975 azioni in circolazione. Le azioni sono state acquisite mediante un esercizio di opzione azionaria e la data di acquisizione, la data del pagamento e la data approssimativa di vendita sono tutte indicate come 08/12/2025, con pagamento in contanti.
Il modulo dichiara che non sono state vendute altre titoli negli ultimi tre mesi e include la dichiarazione del venditore di non essere in possesso di informazioni negative rilevanti non divulgate. Diversi campi identificativi dell'emittente/del depositante risultano vuoti, pertanto il testo del deposito omette il nome del depositante e della persona per conto della quale i titoli dovrebbero essere venduti.
Akero Therapeutics (AKRO) present贸 un Formulario 144 que informa la venta propuesta de 50.000 acciones ordinarias a trav茅s de J.P. Morgan Securities LLC en NASDAQ, con un valor de mercado agregado informado de $2,414,000 y aproximadamente 79,988,975 acciones en circulaci贸n. Las acciones fueron adquiridas mediante un ejercicio de opci贸n sobre acciones y la fecha de adquisici贸n, la fecha de pago y la fecha aproximada de venta figuran todas como 08/12/2025, con pago en efectivo.
El formulario declara que no se vendieron valores en los 煤ltimos tres meses e incluye la representaci贸n del vendedor de no poseer informaci贸n adversa material no divulgada. Varios campos de identificaci贸n del emisor/declarante aparecen en blanco, por lo que el texto de la presentaci贸n omite el nombre del declarante y de la persona en cuya cuenta se vender铆an los valores.
Akero Therapeutics(AKRO)電� J.P. Morgan Securities LLC毳� 韱淀暣 NASDAQ鞐愳劀 氤错喌欤� 50,000欤检潣 毵り皝 鞓堨爼 靷嫟鞚� 氤搓碃頃橂姅 Form 144毳� 鞝滌稖頄堨溂氅�, 氤搓碃霅� 齑� 鞁滉皜鞎§潃 $2,414,000鞚搓碃 氚滍枆欤检嫕靾橂姅 鞎� 79,988,975欤检瀰雼堧嫟. 頃措嫻 欤检嫕鞚� 鞀ろ啞 鞓奠厴 頄夓偓搿� 旆摑霅橃棃瓿� 旆摑鞚�, 瓴办牅鞚� 氚� 鞓堨儊 毵り皝鞚检澊 氇憪 08/12/2025搿� 旮办灛霅橃柎 鞛堨溂氅� 瓴办牅電� 顺勱笀鞙茧 鞚措（鞏挫雼堧嫟.
頃措嫻 靹滌嫕鞚� 歆�雮� 3臧滌洈 雮� 毵る弰霅� 歃濌秾鞚� 鞐嗢潓鞚� 瓿店皽頃橁碃 鞛堨溂氅�, 韺愲Г鞛愲姅 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 氤挫湢頃橁碃 鞛堨 鞎婌潓鞚� 歆勳垹頃橁碃 鞛堨姷雼堧嫟. 鞝滉车霅� 雮挫毄 欷� 鞐煬 氚滍枆鞚�/鞝滌稖鞛� 鞁濍硠 頃勲摐臧� 牍勳柎 鞛堨柎 鞝滌稖 氍胳劀鞐愳劀 氇呾嫓霅� 鞝滌稖鞛愲獏瓿� 頃措嫻 瓿勳爼鞚� 毵る弰鞛愲獏鞚� 雸勲澖霅橃柎 鞛堨姷雼堧嫟.
Akero Therapeutics (AKRO) a d茅pos茅 un formulaire 144 d茅clarant la cession propos茅e de 50 000 actions ordinaires via J.P. Morgan Securities LLC sur le NASDAQ, avec une valeur de march茅 agr茅g茅e d茅clar茅e de 2 414 000 $ et environ 79 988 975 actions en circulation. Les actions ont 茅t茅 acquises par un exercice d'option sur actions et la date d'acquisition, la date de paiement et la date approximative de vente sont toutes indiqu茅es comme le 08/12/2025, le paiement 茅tant en 别蝉辫猫肠别蝉.
Le formulaire indique qu'aucun titre n'a 茅t茅 vendu au cours des trois derniers mois et comprend la d茅claration du vendeur selon laquelle il ne d茅tient pas d'informations n茅gatives importantes non divulgu茅es. Plusieurs champs d'identification de l'茅metteur/de la personne d茅posante sont vides; le texte du d茅p么t omet donc le nom du d茅posant et la personne pour le compte de laquelle les titres doivent 锚tre vendus.
Akero Therapeutics (AKRO) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 50.000 Stammaktien 眉ber J.P. Morgan Securities LLC an der NASDAQ meldet, mit einem angegebenen aggregierten Marktwert von $2,414,000 und ungef盲hr 79,988,975 ausstehenden Aktien. Die Aktien wurden durch eine Aus眉bung einer Aktienoption erworben; Erwerbsdatum, Zahlungsdatum und das ungef盲hre Verkaufsdatum sind alle mit 08/12/2025 angegeben, die Zahlung erfolgt in Bar.
Das Formular gibt an, dass in den letzten drei Monaten keine Wertpapiere verkauft wurden, und enth盲lt die Erkl盲rung des Verk盲ufers, keine nicht offengelegten wesentlichen nachteiligen Informationen zu besitzen. Mehrere Identifikationsfelder des Emittenten/Einreichers sind leer, sodass im vorliegenden Text der Einreichung der Name des Einreichers und die Person, in deren Auftrag die Wertpapiere verkauft werden sollen, fehlt.
- Transaction disclosed under Rule 144, showing formal compliance with regulatory notice requirements
- Use of a major broker (J.P. Morgan Securities LLC) and listing of the securities exchange (NASDAQ)
- Acquisition and payment details provided: stock option exercise, payment in cash, with dates shown
- Key identification fields are blank in the provided content (filer CIK/CCC and named person for whose account the securities are to be sold), limiting context
- Acquisition and sale occur on the same date (08/12/2025), indicating immediate monetization of exercised options as presented in the filing extract
Insights
TL;DR: A small, disclosed insider sale 鈥� 50,000 shares (~$2.41M) 鈥� following an option exercise; size is immaterial versus outstanding shares.
The filing shows an option exercise and same-day proposed sale of 50,000 shares with aggregate market value of $2,414,000 against 79,988,975 shares outstanding, which represents roughly 0.063% of outstanding stock. The transaction was routed through J.P. Morgan Securities LLC on NASDAQ and paid in cash. From a market-impact standpoint, the disclosed size is immaterial to capitalization; from an execution standpoint, the use of Rule 144 and a major broker are routine compliance steps. The form content lacks explicit filer identification in the provided text, limiting assessment of insider role and timing context.
TL;DR: Disclosure aligns with Rule 144 mechanics, but the filing extract omits key identification fields needed for full governance context.
The document explicitly records acquisition by stock option exercise and a proposed sale on the same date, with the seller certifying absence of undisclosed material adverse information and relying on Rule 144 procedures. These elements suggest procedural compliance. However, critical identification fields (filer CIK/CCC and the named person for whose account the securities are to be sold) are blank in the supplied text, which constrains evaluation of insider status, blackout-period compliance, or any pre-existing trading plans.
Akero Therapeutics (AKRO) ha presentato un Modulo 144 che segnala la vendita proposta di 50.000 azioni ordinarie tramite J.P. Morgan Securities LLC sul NASDAQ, con un valore di mercato complessivo riportato pari a $2,414,000 e circa 79,988,975 azioni in circolazione. Le azioni sono state acquisite mediante un esercizio di opzione azionaria e la data di acquisizione, la data del pagamento e la data approssimativa di vendita sono tutte indicate come 08/12/2025, con pagamento in contanti.
Il modulo dichiara che non sono state vendute altre titoli negli ultimi tre mesi e include la dichiarazione del venditore di non essere in possesso di informazioni negative rilevanti non divulgate. Diversi campi identificativi dell'emittente/del depositante risultano vuoti, pertanto il testo del deposito omette il nome del depositante e della persona per conto della quale i titoli dovrebbero essere venduti.
Akero Therapeutics (AKRO) present贸 un Formulario 144 que informa la venta propuesta de 50.000 acciones ordinarias a trav茅s de J.P. Morgan Securities LLC en NASDAQ, con un valor de mercado agregado informado de $2,414,000 y aproximadamente 79,988,975 acciones en circulaci贸n. Las acciones fueron adquiridas mediante un ejercicio de opci贸n sobre acciones y la fecha de adquisici贸n, la fecha de pago y la fecha aproximada de venta figuran todas como 08/12/2025, con pago en efectivo.
El formulario declara que no se vendieron valores en los 煤ltimos tres meses e incluye la representaci贸n del vendedor de no poseer informaci贸n adversa material no divulgada. Varios campos de identificaci贸n del emisor/declarante aparecen en blanco, por lo que el texto de la presentaci贸n omite el nombre del declarante y de la persona en cuya cuenta se vender铆an los valores.
Akero Therapeutics(AKRO)電� J.P. Morgan Securities LLC毳� 韱淀暣 NASDAQ鞐愳劀 氤错喌欤� 50,000欤检潣 毵り皝 鞓堨爼 靷嫟鞚� 氤搓碃頃橂姅 Form 144毳� 鞝滌稖頄堨溂氅�, 氤搓碃霅� 齑� 鞁滉皜鞎§潃 $2,414,000鞚搓碃 氚滍枆欤检嫕靾橂姅 鞎� 79,988,975欤检瀰雼堧嫟. 頃措嫻 欤检嫕鞚� 鞀ろ啞 鞓奠厴 頄夓偓搿� 旆摑霅橃棃瓿� 旆摑鞚�, 瓴办牅鞚� 氚� 鞓堨儊 毵り皝鞚检澊 氇憪 08/12/2025搿� 旮办灛霅橃柎 鞛堨溂氅� 瓴办牅電� 顺勱笀鞙茧 鞚措（鞏挫雼堧嫟.
頃措嫻 靹滌嫕鞚� 歆�雮� 3臧滌洈 雮� 毵る弰霅� 歃濌秾鞚� 鞐嗢潓鞚� 瓿店皽頃橁碃 鞛堨溂氅�, 韺愲Г鞛愲姅 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 氤挫湢頃橁碃 鞛堨 鞎婌潓鞚� 歆勳垹頃橁碃 鞛堨姷雼堧嫟. 鞝滉车霅� 雮挫毄 欷� 鞐煬 氚滍枆鞚�/鞝滌稖鞛� 鞁濍硠 頃勲摐臧� 牍勳柎 鞛堨柎 鞝滌稖 氍胳劀鞐愳劀 氇呾嫓霅� 鞝滌稖鞛愲獏瓿� 頃措嫻 瓿勳爼鞚� 毵る弰鞛愲獏鞚� 雸勲澖霅橃柎 鞛堨姷雼堧嫟.
Akero Therapeutics (AKRO) a d茅pos茅 un formulaire 144 d茅clarant la cession propos茅e de 50 000 actions ordinaires via J.P. Morgan Securities LLC sur le NASDAQ, avec une valeur de march茅 agr茅g茅e d茅clar茅e de 2 414 000 $ et environ 79 988 975 actions en circulation. Les actions ont 茅t茅 acquises par un exercice d'option sur actions et la date d'acquisition, la date de paiement et la date approximative de vente sont toutes indiqu茅es comme le 08/12/2025, le paiement 茅tant en 别蝉辫猫肠别蝉.
Le formulaire indique qu'aucun titre n'a 茅t茅 vendu au cours des trois derniers mois et comprend la d茅claration du vendeur selon laquelle il ne d茅tient pas d'informations n茅gatives importantes non divulgu茅es. Plusieurs champs d'identification de l'茅metteur/de la personne d茅posante sont vides; le texte du d茅p么t omet donc le nom du d茅posant et la personne pour le compte de laquelle les titres doivent 锚tre vendus.
Akero Therapeutics (AKRO) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 50.000 Stammaktien 眉ber J.P. Morgan Securities LLC an der NASDAQ meldet, mit einem angegebenen aggregierten Marktwert von $2,414,000 und ungef盲hr 79,988,975 ausstehenden Aktien. Die Aktien wurden durch eine Aus眉bung einer Aktienoption erworben; Erwerbsdatum, Zahlungsdatum und das ungef盲hre Verkaufsdatum sind alle mit 08/12/2025 angegeben, die Zahlung erfolgt in Bar.
Das Formular gibt an, dass in den letzten drei Monaten keine Wertpapiere verkauft wurden, und enth盲lt die Erkl盲rung des Verk盲ufers, keine nicht offengelegten wesentlichen nachteiligen Informationen zu besitzen. Mehrere Identifikationsfelder des Emittenten/Einreichers sind leer, sodass im vorliegenden Text der Einreichung der Name des Einreichers und die Person, in deren Auftrag die Wertpapiere verkauft werden sollen, fehlt.
FAQ
How many shares did Akero Therapeutics (AKRO) file to sell on Form 144?
When were the shares acquired and when is the approximate sale date listed for AKRO?
Which broker and exchange are named in the AKRO Form 144?
Does the filing show any AKRO securities sold in the past three months?
What was the nature of the acquisition for the AKRO shares being sold?
